Key result
Uninterrupted lipid-lowering therapy during pregnancy in women with familial hypercholesterolemia illustrates a hypothetical protective impact against cumulative LDL-C burden and ASCVD events.
Why the study?
Does lipid-lowering therapy during pregnancy reduce cumulative LDL-C burden and ASCVD risk in women with familial hypercholesterolemia?
Does lipid-lowering therapy during pregnancy reduce cumulative LDL-C burden and ASCVD risk in women with familial hypercholesterolemia?
Uninterrupted lipid-lowering therapy during pregnancy in women with familial hypercholesterolemia may hypothetically reduce cumulative LDL-C burden and ASCVD risk.
May inform risk-benefit discussions for lipid-lowering continuity in familial hypercholesterolemia; leaves open prospective pregnancy trials.
Schematic representation of cumulative LDL-C burden and risk of ASCVD events over the lifespan in women with familial hypercholesterolemia (FH) and two pregnancies. All scenarios assume early initiation of lipid-lowering therapy (LLT). Curves illustrate cumulative exposure with LLT (shown in green) and without LLT (shown in orange) during pregnancy. The blue curve illustrates women without FH. The black horizontal line indicates the threshold for risk for symptomatic cardiovascular disease.(9) The curve with uninterrupted therapy represents a hypothetical scenario illustrating the potential protective impact of LLT.9
No takes yet. Share an insight, caveat, or question.
Paulina Stürzebecher (2025) studied Familial hypercholesterolemia. Lipid-lowering therapy (LLT) vs. Without LLT was evaluated on Cumulative LDL-C burden and risk of ASCVD events. Uninterrupted lipid-lowering therapy during pregnancy in women with familial hypercholesterolemia illustrates a hypothetical protective impact against cumulative LDL-C burden and ASCVD events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: